Compare NGG & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGG | VRTX |
|---|---|---|
| Founded | 1990 | 1989 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | EDP Services |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.7B | 115.7B |
| IPO Year | N/A | 2006 |
| Metric | NGG | VRTX |
|---|---|---|
| Price | $90.45 | $465.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 28 |
| Target Price | N/A | ★ $537.64 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | N/A | ★ 15.32 |
| Revenue | N/A | ★ $2,488,652,000.00 |
| Revenue This Year | N/A | $10.79 |
| Revenue Next Year | $10.73 | $10.14 |
| P/E Ratio | $115.91 | ★ $30.67 |
| Revenue Growth | N/A | ★ 46.20 |
| 52 Week Low | $62.76 | $362.50 |
| 52 Week High | $94.64 | $516.50 |
| Indicator | NGG | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 46.10 |
| Support Level | $89.14 | $453.97 |
| Resistance Level | $94.64 | $473.78 |
| Average True Range (ATR) | 1.47 | 16.32 |
| MACD | -0.50 | -1.80 |
| Stochastic Oscillator | 30.10 | 25.38 |
National Grid owns and operates the electric transmission system in England and Wales. It sold the bulk of its UK gas transmission business in fiscal 2023 to fund the acquisition of PPL's UK power distribution assets. In the Northeastern United States, it serves electricity and gas customers combined in three states. It also owns regulated transmission and electricity generation in the United States, metering services, merchant transmission lines in the UK, and the Grain (UK) liquefied natural gas facility.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.